Navigation Links
Oncothyreon reports full year and fourth quarter 2008 financial results
Date:3/9/2009

--------- --------- --------- --------- Income (loss) per share - Diluted.................... $ 1.06 $ (0.26) $ 0.36 $ (1.04) --------- --------- --------- --------- Shares used to compute basic income (loss) per share.... 19,492 19,486 19,491 19,486 --------- --------- --------- --------- Shares used to compute diluted income (loss) per share...................... 19,572 19,486 19,572 19,486 --------- --------- --------- --------- Oncothyreon Inc. Consolidated Balance Sheet Data (in thousands of U.S. dollars) (unaudited) December 31, December 31, 2008 2007 Cash, cash equivalents and short term investments................................... $ 19,166 $ 24,186 Total assets................................... 24,971 36,218 Total long-term liabilities.................... 393 12,526 Stockholders' equity........................... 20,717 12,019 Common shares outstanding...................... 19,492 19,486


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
2. Oncothyreon to present at BIO CEO & Investor Conference 2009
3. Oncothyreon reports third quarter 2008 financial results
4. Oncothyreon to present at Rodman & Renshaw Annual Global Investment Conference
5. Oncothyreon announces November 6th webcast of third quarter 2008 financial results and corporate update conference call
6. Oncothyreon to present at BIO Investor Forum 2008
7. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
8. Oncothyreon announces prioritization plan for development programs
9. Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
10. Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
11. Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... December 23, 2014 The ... such as its definition, classification, application and ... specification, manufacturing process, and product cost structure. ... applications. The analysis also covers upstream raw ... industry development trend and proposals. In the ...
(Date:12/24/2014)... BEIJING , Dec. 23, 2014 ... or the "Company"), a leading fully integrated plasma-based ... today announced that its majority-owned subsidiary, Shandong Taibang ... Practices ("GMP") certification from the China Food and ... factor production facility. As previously disclosed in the ...
(Date:12/24/2014)... Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... filed a Clinical Trial Application (CTA) with the ... Agency (MHRA) seeking regulatory approval to initiate clinical trials ... Citrate. Contingent on the Company receiving CTA ... I trial to assess the safety, tolerability and dose ...
(Date:12/22/2014)... RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a ... of autologous cell therapies, announced today the publication of ... conjunction with co-authors from Kyoto University and the University ... clinical research using dermal sheath cup (DSC) cells to ... paper entitled " Hair Follicle Dermal Stem Cells Regenerate ...
Breaking Biology Technology:Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5
... ... of eCommerce, CRM and business intelligence solutions, today announced that Industrial Training International (ITI) ... five divisions: Training, Field Services, Certification, Bookstore, and E-Learning. , ... Northbrook, IL, and Woodland, WA ...
... ... Wilson has joined the company as Vice President of Finance and Administration. Mr. Wilson ... corporate office in Lake Forest, CA. , ... Healthcare Data Solutions announced that Mitchell Wilson has joined the company ...
... EMERYVILLE, Calif. , May 4 Bionovo, Inc. (Nasdaq: BNVI ... fiscal year 2010 ended March 31, 2010 on Tuesday, May 11, ... financial results on Tuesday, May 11, 2010 at 5:00 p.m. ET ... Interested parties can access the call by ...
Cached Biology Technology:EDL Consulting Chosen to Implement Visionary Cloud-based eCommerce-Driven Learning Management System 2EDL Consulting Chosen to Implement Visionary Cloud-based eCommerce-Driven Learning Management System 3Healthcare Data Solutions Announces New Executive Team Member 2Bionovo, Inc. to Announce First Quarter Fiscal Year 2010 Financial Results on Tuesday, May 11, 2010 2
(Date:12/19/2014)...   LaunchKey , the first decentralized mobile authentication ... of Things era, today announced the close of $3 ... led by Metamorphic Ventures with participation from ENIAC Ventures, ... others.  LaunchKey has raised $4 million to date, and ... and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ... robust – with the clinical data to back it ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the ... APAC Region 2015-2019"  report to their offering. ... market is advances in technology. With continuous advances ... solutions to the latest standard that meets the ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... 2008) A new study by the Bronx Zoo-based ... the Greater Yellowstone Ecosystem have apparently hopped into oblivion. ... of the journal Oryx, also speculates that the disappearance ... a variety of other prey species and their predators. ...
... crucial proteins in our bodies must fold into complex shapes ... to move them around, to speed up important chemical reactions ... "off" to affect which proteins our cells make. Recently, ... genetic code into protein-can act a lot like a protein ...
... of shrimp and fish in tropical coastal areas is ... poverty, but in fact this cultivation has negative consequences ... Daniel A. Bergquist of Uppsala University, Sweden, has studied ... The cultivating of fish and shellfish in artificial ...
Cached Biology News:Hareless: Yellowstone's rabbits have vanished, study says 2Stanford researchers make first direct observation of 3-D molecule folding in real time 2Stanford researchers make first direct observation of 3-D molecule folding in real time 3Stanford researchers make first direct observation of 3-D molecule folding in real time 4Stanford researchers make first direct observation of 3-D molecule folding in real time 5Global trade in tiger shrimp threatens environment 2